Featured Research

from universities, journals, and other organizations

Turoctocog alfa in patients with hemophilia A: Added benefit not proven, article finds

Date:
April 22, 2014
Source:
Institute for Quality and Efficiency in Health Care
Summary:
As no relevant studies and no valid data are available, the added benefit of turoctocog alfa over other blood-clotting agents is not proven, a publication concludes. Turoctocog alfa (trade name: NovoEight) has been approved since November 2013 for the prevention and treatment of bleeding in patients with hemophilia A.

Turoctocog alfa (trade name: NovoEight) has been approved since November 2013 for the prevention and treatment of bleeding in patients with hemophilia A. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new active ingredient offers an added benefit over the appropriate comparator therapy.

According to the findings, an added benefit of turoctocog alfa is not proven. As no relevant study is available for comparison with the appropriate comparator therapy, the benefit assessment of the drug manufacturer is based on its own deliberations and assumptions, for which, however, a valid data basis is lacking.

Other blood clotting factors VIII as comparator therapy

The deficiency in blood clotting factor VIII is inherited and linked to the X chromosome. This is why hemophilia A is almost exclusively seen in men, as they only have one X chromosome in their DNA. The defective blood clotting leads to strong spontaneous bleeding (or bleeding after injuries) in joints, muscles, and internal organs.

Turoctocog alfa is produced biotechnologically (recombinant) and is supposed to compensate the deficiency in blood clotting factor, i.e. the tendency to bleed. As prophylactic treatment it has be injected intravenously every 2 to 3 days.

The Federal Joint Committee (G-BA) specified blood clotting factor VIII agents produced biotechnologically or gained from human plasma as the appropriate comparator therapy.

Market entry does not prove added benefit

Out of various options, the manufacturer chose blood clotting factor VIII octocog alfa as a comparator, but limited its selection to a single third-generation agent of octocog alfa (trade name: Advate). This restriction does not correspond to the comparator therapy specified by the G-BA, as according to the G-BA's requirements, for a complete comparison all agents containing the active ingredient octocog alfa must be considered.

But even for the comparison chosen by the manufacturer, no relevant studies are presented. Instead the manufacturer bases its benefit assessment on fundamental deliberations and assumptions, which are inferred from different publications and statistics.

For instance, from the manufacturer's point of view, an "improvement in the safety of health care" and a "better integration of patients with hemophilia into a normal social life" already arise through market entry. However, an added benefit cannot be inferred from market entry alone.

Medical relevance for patients unclear

In comparison with octocog alfa the manufacturer claims an advantage for turoctocog alfa, as the new active ingredient can be stored at higher temperatures (up to 30 C) than octocog alfa (25C). Particularly during the summer months and during travels to warmer countries, this is supposed to be beneficial and thus enable a "better integration of patients with hemophilia into a normal social life."

However, whether this difference in storage temperatures is medically relevant for patients needs to be investigated and proven in studies. The manufacturer's dossier provides no such data.

Therefore, the manufacturer's deliberations are overall not suited to assess the patient-relevant beneficial and harmful effects of turoctocog alfa versus the appropriate comparator therapy. The added benefit of the new active ingredient is therefore not proven.


Story Source:

The above story is based on materials provided by Institute for Quality and Efficiency in Health Care. Note: Materials may be edited for content and length.


Cite This Page:

Institute for Quality and Efficiency in Health Care. "Turoctocog alfa in patients with hemophilia A: Added benefit not proven, article finds." ScienceDaily. ScienceDaily, 22 April 2014. <www.sciencedaily.com/releases/2014/04/140422113359.htm>.
Institute for Quality and Efficiency in Health Care. (2014, April 22). Turoctocog alfa in patients with hemophilia A: Added benefit not proven, article finds. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/04/140422113359.htm
Institute for Quality and Efficiency in Health Care. "Turoctocog alfa in patients with hemophilia A: Added benefit not proven, article finds." ScienceDaily. www.sciencedaily.com/releases/2014/04/140422113359.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins